Regen BioPharma Inc (RGBP)

[OTCShotCaller]

Portrait Of A Rising Global Super Star Poised For Greatness

Key Take-Away: Disruptive Biotechnology in the mRNA Therapeutics Space- The Future of Medicine

Regen BioPharma,Inc(OTCMKTS:RGBP)
Powerful Run Brewing As Company Looks to Crush the Competition
By Boe Rimes- June 14, 2021

Regen BioPharma is making an explosive move up the charts since reversing up off its base of $0.01. Microcap Daily initially covered RGBP in April 2021 when the stock skyrocketed from triple zeroes to highs of $0.081 after Regen and its subsidiary KLS entered into an agreement with Oncology Pharma, Inc. whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of intellectual property for the treatment of pancreatic cancer for a term of fifteen years from April 7, 2021. The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.

Furthermore, The Company is currently in the process of updating its filings and preparing outstanding 10Q and 10k reports in order to up list to fully reporting OTCQB “Pink Current” Tier.

After a brief respite RGPB is making a power house move up the charts again looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi-dollars and Enzolytics nearly hit $1.00 shortly after going Pink Current. RGBP is in beast mode right now and is the most talked about small cap stock; a break over $0.082 and its blue skies ahead.

RGBP buyout rumors abound; according to many investors it appears there may be a Potential Merger-Acquisition looming with Precigen OR another Big Pharma, and if so, it would make perfect sense for the following reasons: The CEO of Precigen (PGEN) Helen Sabzevari is on RGBP’s Scientific Advisory Board. PGEN trades on NASDAQ with a Market Cap of $1.3B and has an extensive clinical trials pipeline in Immunology-Oncology that includes development of mRNA vaccine therapies. https://precigen.com/about.

PGEN is in the same clinical therapeutic space of Oncology-Immunology candidate drug development that RGBP is in. 100% identical including the same mRNA vaccine technology. Therefore, logically speaking it would make sense if PGEN buys-out RGBP OR does a Merger Acquisition and the motive to do this are the numerous valuable Patents RGBP owns that have Billion Dollar Market Capacity. Recently we see Koos on an aggressive campaign to pull everything together about RGBP in the shortest amount of time to apparently ready the company for SALE! If you look closely at his recent actions it very clearly points to this.

Regen BioPharma is a publicly traded biotechnology company focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.

The Company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP owns a valuable patent porfolio.

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses. The Company’s products include HemaXellerate, a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.

HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS. The United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)

dCellVax Breast Cancer – dCellVax – IND #16200. CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.” Establishment of safety will allow for rapid expansion of patient numbers. Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program.

DiffronC – Myelodysplastic Syndrome Gene Silencing – DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells. Silencing using DiffronC induces differentiation of cancer cells. Initial indication is treatment of myelodysplastic syndrome. Other indications include solid tumors and acute leukemia.

Telomeres & Genomic Integrity: Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres. Telomeres are protective structures at the ends of chromosomes that enable cell divisions. Telomere attrition is involved in aging, cancer and genetic mutations. The Company is developing drugs that modulate telomere maintenance. In pre-clinical development for indications of solid cancers and acute leukemia.

In the CBD space RGBP researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company’s small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn’s disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies available to IBD sufferers.

Recently it's been speculated that Koos intends to sell the company, and if so, let’s objectively review why that might be:

1). on 4/8/21 Koos files an 8K that in and of itself is a dead give-a-away of what he’s up to. The question begs why would he file an 8K that specifically gives himself exclusive control of voting rights in negotiations for the sale of the company during the bidding process that’s specifically intended to prevent a Hostile Take Over? And in doing this he states quote: “persons of interest who want to ACQUIRE RGBP must negotiate directly.” This is in reference to himself having sole control of voting rights that this 8K gives him. Other words, negotiations for sale of the company can’t go around him to his board which is a typical move in any hostile take over. This by itself reveals what he’s up to in addition to MANY other factors shown below. https://sec.report/Document/0001607062-21-000145/

2). he recently hired a Firm to get OTC current with FULL disclosure reporting. This has to do not only with SEC compliance to remain listed on the OTC beyond September 2021 but ALSO it provides transparency for any potential Big Pharma buyers that would never consider buying a company otherwise.

3). on 6/1/21 he files another 8K that has to do with resolving a lawsuit. This would be important to any potential buyers for reason a pending unresolved lawsuit would likely complicate negotiations of a buy out, or it would be a deterrent altogether. https://sec.report/Document/0001607062-21-000145/

4). we see him moving to get all his expired Patents updated. Logically this move would be consistent with preparing for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline.

5). lastly he’s not updating the company website that’s been outdated for years. Why would he invested time, energy, and money in updating his company website if he’s about to sell the company?

This is not an attempt to read Koos' mind, however the cluster of all these moves he's made combined within a narrow time span seems highly indicative of an intention to sell the company and the revelation of that is rapidly forthcoming.

Link to above Article:

https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-powerful-run-brewing-as-company-looks-to-crush-the-competition-hemaxellerate/131947/?amp&__twitter_impression=true&fbclid=IwAR3NqAzavR7a27Ql0abPPUuvtSGSWz0MoWLfcL1De1-vxJyDc-Y-YR33dMU